Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Receives Consensus Rating of “Hold” from Analysts

Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) have been given an average recommendation of “Hold” by the five research firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $41.00.

ETON has been the topic of several recent research reports. Wall Street Zen raised shares of Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday. B. Riley Financial raised their target price on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, March 20th. Craig Hallum raised their target price on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, March 20th. Zacks Research cut shares of Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, April 17th. Finally, HC Wainwright raised their target price on shares of Eton Pharmaceuticals from $52.00 to $57.00 and gave the stock a “buy” rating in a report on Friday, May 15th.

Eton Pharmaceuticals Stock Up 1.8%

Shares of ETON opened at $32.15 on Tuesday. Eton Pharmaceuticals has a 12 month low of $13.09 and a 12 month high of $35.66. The firm’s 50 day moving average is $28.50 and its 200-day moving average is $21.25. The stock has a market capitalization of $880.59 million, a PE ratio of -459.22 and a beta of 0.87. The company has a current ratio of 1.21, a quick ratio of 0.88 and a debt-to-equity ratio of 0.62.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its earnings results on Thursday, May 14th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.05). Eton Pharmaceuticals had a negative return on equity of 5.68% and a negative net margin of 1.70%.The business had revenue of $24.27 million for the quarter, compared to the consensus estimate of $22.31 million. Equities research analysts forecast that Eton Pharmaceuticals will post 0.75 EPS for the current year.

Insider Transactions at Eton Pharmaceuticals

In related news, insider David Krempa sold 42,797 shares of Eton Pharmaceuticals stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $33.39, for a total value of $1,428,991.83. Following the transaction, the insider directly owned 25,249 shares of the company’s stock, valued at $843,064.11. This trade represents a 62.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold 100,000 shares of company stock valued at $3,229,921 over the last quarter. Company insiders own 16.49% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Deutsche Bank AG increased its stake in Eton Pharmaceuticals by 4.9% in the fourth quarter. Deutsche Bank AG now owns 18,249 shares of the company’s stock valued at $309,000 after acquiring an additional 850 shares during the last quarter. Intech Investment Management LLC increased its stake in Eton Pharmaceuticals by 11.1% in the fourth quarter. Intech Investment Management LLC now owns 12,421 shares of the company’s stock valued at $210,000 after acquiring an additional 1,244 shares during the last quarter. State of Wyoming increased its stake in Eton Pharmaceuticals by 16.4% in the first quarter. State of Wyoming now owns 9,498 shares of the company’s stock valued at $234,000 after acquiring an additional 1,337 shares during the last quarter. Man Group plc increased its stake in Eton Pharmaceuticals by 6.0% in the second quarter. Man Group plc now owns 23,754 shares of the company’s stock valued at $338,000 after acquiring an additional 1,350 shares during the last quarter. Finally, Quarry LP bought a new position in Eton Pharmaceuticals in the third quarter valued at approximately $37,000. 27.86% of the stock is owned by institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.